LifeTechnologies公司（納斯達(dá)克代碼：LIFE）是一家致力于改善人類環(huán)境的全球生物技術(shù)公司。我們的儀器、耗材和服務(wù)可協(xié)助研究者加速科學(xué)探索與開(kāi)發(fā)，從而讓生命變得更加美好。我們的客戶遍及生物學(xué)各個(gè)領(lǐng)域，努力加速推進(jìn)個(gè)性化**、再生科學(xué)、分子診斷、農(nóng)業(yè)和環(huán)境的研究以及21世紀(jì)的法醫(yī)鑒定。生命科技公司2009年的銷售額為33億美元，全球雇員約為9000人，遍及160個(gè)國(guó)家，并擁有將近3900項(xiàng)知識(shí)產(chǎn)權(quán)**及專有許可證。LifeTechnologies公司由Invitrogen公司和AppliedBiosystems公司合并而成，制造體外診斷產(chǎn)品和僅供研究的產(chǎn)品。更多關(guān)于我們?nèi)绾纹鹱饔玫男畔?，?qǐng)?jiān)L問(wèn)網(wǎng)站www.lifetechnologies.com。
Life Technologies的**聲明

   本新聞稿包含關(guān)于我們預(yù)期結(jié)果的前瞻性陳述，且涉及多種風(fēng)險(xiǎn)和不確定因素。本新聞稿中的部分內(nèi)容，包括但不限于，行業(yè)趨勢(shì)、LifeTechnologies的業(yè)務(wù)計(jì)劃、目標(biāo)、預(yù)期和戰(zhàn)略的陳述，均包含受各種風(fēng)險(xiǎn)和不確定因素影響的前瞻性陳述，這些風(fēng)險(xiǎn)和不確定因素可能導(dǎo)致實(shí)際結(jié)果和事件與前瞻性陳述中明示或暗示的有重大差異。任何不屬于歷史事實(shí)的陳述均為前瞻性陳述?？梢酝ㄟ^(guò)一些特定用詞，如“相信”、“計(jì)劃”、“意圖”、“預(yù)期”、“目標(biāo)”、“估計(jì)”、“期望”，和/或?qū)?lái)時(shí)態(tài)、條件句結(jié)構(gòu)（如“將”、“可能”、“可以”、“應(yīng)當(dāng)”等）或類似的表達(dá)方式，來(lái)識(shí)別一部分前瞻性陳述?？赡芤l(fā)實(shí)際結(jié)果與前瞻性陳述有重大差異的一些重要因素，在LifeTechnologies向美國(guó)證券交易委員會(huì)提交的文件中皆有詳述。LifeTechnologies不承擔(dān)任何更新或修改此類前瞻性陳述，以反映后續(xù)事件或情形的義務(wù)。

LifeTechnologies Readies Researchers for Transition from Benchtop toBedside
Tools and reagents pre-configured to supportcell therapy clinical translation
CARLSBAD, Calif. – June 16, 2010 – Life Technologies Corporation(NASDAQ: LIFE) today announced the formation of GIBCO? Cell Therapy Systems (CTS?), which will offer the life scienceindustry’s widest array of products to support cell therapyapplications, including regenerative medicine. Specificallydesigned to help cell therapy practitioners accelerate thetransition from research to clinical applications, the productportfolio will include a broad and deep offering of Invitrogendevices and reagents.
Cell therapy practitioners today spend a lot of time and moneyassembling and qualifying the tools and reagents required to move acell therapy concept from a laboratory environment to the clinic ina regulatory compliant and highly supported process. Cell-basedtherapies have hundreds of potential applications addressing unmetmedical needs, including neurological disorders, heart disease,cancer, auto-immune disease, infectious disease, as well as tissuerepair where conventional pharmaceuticals may be ineffective. Withthe regenerative medicine field experiencing explosive growth, from$1.6 billion to $15 - $20 billion over the next 15 years1, LifeTechnologies is building a portfolio of bundled tools and reagentsto address this challenge and help researchers accelerate theprocess of moving their potential solutions into a clinicalenvironment.
“Documentation is a critical aspect of bringing novel celltherapies to the clinic,” said Dr. Larry Couture, Senior VicePresident and Founding Director of the Center for AppliedTechnology Development; Director for the Center for Biomedicine andGenetics at the City of Hope in Duarte, California. “Having properquality systems in place, appropriate documentation, and a stablesupply chain is critical, both in the pre-clinical developmentphase, as well as further down the road during clinicaltrials.”
The CTS product portfolio will provide media, reagents, enzymes,buffers, growth factors, selection-beads and magnets, and othercomponents of integrated workflow solutions. The high-qualitymaterials will come with easily accessible documentation, such ascertificates of analysis and certificates of origin. Moreover, theproducts will be backed up with the highest level of technical,regulatory and web-based support.
“We’ve leveraged our expertise, as well as our broad and deepproduct portfolio to create workflow solutions for cell therapythat will help investigators move their research applications intothe clinic more quickly and efficiently, while enhancing patientsafety,” said Paul Pickering, General Manager of Cell TherapySystems at Life Technologies. “We anticipate that this offeringwill enable us to form collaborations with key industry leaders,and help reduce their burden in qualifying tools and reagents asthey prepare to move their cell therapy concepts into the clinic,which will ultimately help improve the human condition and addressunmet medical need.”
1 Scientia Advisors new market review, quoted in April 23, 2010article from Fierce Biotech.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a globalbiotechnology tools company dedicated to improving the humancondition. Our systems, consumables and services enable researchersto accelerate scientific exploration, driving to discoveries anddevelopments that make life even better. Life Technologiescustomers do their work across the biological spectrum, working toadvance personalized medicine, regenerative science, moleculardiagnostics, agricultural and environmental research, and 21stcentury forensics. Life Technologies had sales of $3.3 billion in2009, employs approximately 9,000 people, has a presence inapproximately 160 countries, and possesses a rapidly growingintellectual property estate of approximately 3,900 patents andexclusive licenses. Life Technologies was created by thecombination of Invitrogen Corporation and Applied Biosystems Inc.,and manufactures both in-vitro diagnostic products and research useonly-labeled products. For more information on how we are making adifference, please visit our website:http://www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about ouranticipated results that involve risks and uncertainties. Some ofthe information contained in this press release, including, but notlimited to, statements as to industry trends and LifeTechnologies'''''''''''''''''''''''''''''''' plans, objectives,expectations and strategy for its business, containsforward-looking statements that are subject to risks anduncertainties that could cause actual results or events to differmaterially from those expressed or implied by such forward-lookingstatements. Any statements that are not statements of historicalfact are forward-looking statements. When used, the words"believe," "plan," "intend," "anticipate," "target," "estimate,""expect" and the like, and/or future tense or conditionalconstructions ("will," "may," "could," "should," etc.), or similarexpressions, identify certain of these forward-looking statements.Important factors which could cause actual results to differmaterially from those in the forward-looking statements aredetailed in filings made by Life Technologies with the Securitiesand Exchange Commission. Life Technologies undertakes no obligationto update or revise any such forward-looking statements to reflectsubsequent events or circumstances.
Products are For Research Use Only. Not intended for any animal orhuman therapeutic or diagnostic use.
Life Technologies Contact